December 19, 2014 4:36 AM ET

Pharmaceuticals

Company Overview of Chiasma (Israel) ltd.

Company Overview

Chiasma (Israel) ltd., a biopharmaceutical company, develops oral drugs based on transient permeability enhancer system. The company offers oral octreotide acetate for the treatment of acromegaly. Its pipeline products include novel drugs which addresses unmet needs for well-defined markets. The company focuses primarily on orphan indications. The company was founded in 2001 and is based in Jerusalem, Israel. Chiasma (Israel) ltd. operates as a subsidiary of Chiasma, Inc.

10 Hartom Street

Jerusalem,  91450

Israel

Founded in 2001

Phone:

972 2 571 5885

Fax:

972 2 571 5886

Key Executives for Chiasma (Israel) ltd.

Chief Executive Officer and Director
Vice President of Finance and Administration
Age: 44
Vice President of BD and Commercial Planning
IP Counsel
Vice President of Quality Assurance & Regulatory Affairs
Compensation as of Fiscal Year 2014.

Chiasma (Israel) ltd. Key Developments

Roche AG Cancels $600 Million Chiasma Deal

Roche AG has notified Israeli startup Chiasma that it has cancelled a commercial agreement for a product for treatment of acromegaly (gigantism). The agreement, signed in February 2013, would have generated $600 million for Chiasma's investors, had it been fully implemented. Due to its premature cancelation, Chiasma's revenue from the deal to date totaled only a $65 million advance and several more tens of millions of dollars as payments for milestones.

Roche and Chiasma Announce Collaboration to Develop and Commercialize Chiasma's Octreolin(R) for acromegaly and neuroendocrine tumors

Roche and Chiasma announced that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreolin is an investigational oral form of the peptide octreotide, a somatostatin analog that is commercially available only by injection. Octreolin is currently in a pivotal phase 3 clinical trial for acromegaly. Under the terms of the agreement, Roche received a worldwide exclusive license to Octreolin, and will assume responsibility for the commercialization of Octreolin. Genentech will market the product in the United States after US FDA approval. Chiasma will continue development through completion of the pivotal phase 3 clinical trial for acromegaly. The arrangement includes an upfront payment to Chiasma of $65 million, future considerations of up to $530 million in development and commercial milestones, as well as tiered, double-digit royalties on Octreolin net sales. Evercore Partners served as Chiasma's financial advisor on the transaction, and Latham & Watkins LLP served as its legal counsel.

Similar Private Companies By Industry

Company Name Region
LycoRed Ltd. Middle East/Africa
Vecta Ltd. Middle East/Africa
Scigen Israel Limited Middle East/Africa
BioVent Ltd. Middle East/Africa
Biotechnology General (Israel) Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Chiasma (Israel) ltd., please visit www.chiasmapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.